Fragment-Based Drug Discovery - Getting in Shape
Doris Hafenbradl, Biofocus, speaking at Discovery Chemistry Congress 2012.
The Versatility of Fragment Screening Approaches and the Application of Fragment Binding Information in Durg Discovery
Stefan Geschwindner, AstraZeneca, speaking at Discovery Chemistry Congress 2012.
Challenges of an Open Access Screening Platform in Academia
Edgar Specker, Leibniz Institute of Molecular Pharmacology, speaking at European Lab Automation 2012
Defence and Adaptation in Drug-Mediated Liver Toxicity
Christopher Goldring, University of Liverpool, speaking at ADME & Predictive Toxicology Europe 2012
Integration of Parallel Systhesis, Compound Management and Screening in Support to the Itlian National Chemical Collection Center
Alberto Bresciani, IRBM Science Park, speaking at European Lab Automation 2012
Capacitive Immunosensors – A Tool for Detection Where Sensitivity of Conventional ELISA is Not Sufficient
Prof. Bo Mattiasson, Lund University, speaking at Advances in Biodetection and Biosensors 2012.
Rationalizing ADME in the Current Regulatory and Business Environment
Robert Guttendorf, Aclairo Pharmaceutical Development Group, speaking at ADME & Predictive Toxicology Europe
Fragment-Based Screening and Structure-Based Design at ICR: Discovering High Quality Leads in Cancer Drug Discovery
Rob Van Montfort, Institute of Cancer Research, speaking at Discovery Chemistry Conference 2012.
Improvement of Cell Culture Technology for Primary Cells and Stem Cell Manipulation
Dr Veit Bergendahl, Miltenyi Biotec GmbH, speaking at Cell Culture 2012